StreetInsider.com News Articles

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Mon, 20 Jul 2026 07:30:00 -0400

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®)

Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered and wild-type overexpressing tumors. Signal activity including confirmed partial responses in heavily pretreated patients in multiple tumor types.
Differentiated safety profile: No dose-limiting toxicities and no FGFR inhibitor-class toxicities observed, supporting a potentially broader therapeutic index than approved FGFR tyrosine kinase inhibitors (TKIs).
Potential to expand the addressable FGFR3 population: Unlike FGFR TKIs, which are restricted to the ~15–20%

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Mon, 20 Jul 2026 07:30:00 -0400

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®)
Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered and wild-type overexpressing tumors. Signal activity including confirmed partial responses in heavily pretreated patients in multiple tumor types.
Differentiated safety profile: No dose-limiting toxicities and no FGFR inhibitor-class toxicities observed, supporting a potentially broader therapeutic index than approved FGFR tyrosine kinase inhibitors (TKIs).
Potential to expand the addressable FGFR3 population: Unlike FGFR TKIs, which are restricted to the ~15–20%

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Mon, 20 Jul 2026 07:30:00 -0400

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®)
Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered and wild-type overexpressing tumors. Signal activity including confirmed partial responses in heavily pretreated patients in multiple tumor types.
Differentiated safety profile: No dose-limiting toxicities and no FGFR inhibitor-class toxicities observed, supporting a potentially broader therapeutic index than approved FGFR tyrosine kinase inhibitors (TKIs).
Potential to expand the addressable FGFR3 population: Unlike FGFR TKIs, which are restricted to the ~15–20%

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Mon, 20 Jul 2026 07:30:00 -0400

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®)
Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered and wild-type overexpressing tumors. Signal activity including confirmed partial responses in heavily pretreated patients in multiple tumor types.
Differentiated safety profile: No dose-limiting toxicities and no FGFR inhibitor-class toxicities observed, supporting a potentially broader therapeutic index than approved FGFR tyrosine kinase inhibitors (TKIs).
Potential to expand the addressable FGFR3 population: Unlike FGFR TKIs, which are restricted to the ~15–20%

Form 3 Biohaven Ltd. For: Jul 09 Filed by: Volles Warren Karl

Fri, 17 Jul 2026 18:00:00 -0400
si-local-file:///var/storage/secattach/20260717/26785361.html

Form 3 Biohaven Ltd. For: Jul 09 Filed by: Volles Warren Karl

Fri, 17 Jul 2026 18:00:00 -0400
si-local-file:///var/storage/secattach/20260717/26785361.html

Form 8-K Biohaven Ltd. For: Jul 09

Thu, 09 Jul 2026 17:11:00 -0400
si-local-file:///var/storage/secattach/20260709/26753914.html

Form 8-K Biohaven Ltd. For: Jul 09

Thu, 09 Jul 2026 17:11:00 -0400
si-local-file:///var/storage/secattach/20260709/26753914.html

Biohaven names new discovery head as CSO shifts to part-time role

Thu, 09 Jul 2026 17:01:15 -0400

Biohaven Ltd. (NYSE: BHVN) announced leadership changes in its scientific organization, effective July 13, 2026, according to a company statement.
David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, where he will lead the company's internal drug-discovery organization and oversee research programs.
Bruce Car, the company's current Chief Scientific Officer, is retiring from that role and will transition to a newly created part-time position of Chief Innovation Officer. In that capacity, Dr. Car will focus on scientific initiatives and external collaborations, including work related to the company's partnership with Bexorg, Inc. Dr. Car will continue to serve

Biohaven names new discovery head as CSO shifts to part-time role

Thu, 09 Jul 2026 17:01:15 -0400

Biohaven Ltd. (NYSE: BHVN) announced leadership changes in its scientific organization, effective July 13, 2026, according to a company statement.
David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, where he will lead the company's internal drug-discovery organization and oversee research programs.
Bruce Car, the company's current Chief Scientific Officer, is retiring from that role and will transition to a newly created part-time position of Chief Innovation Officer. In that capacity, Dr. Car will focus on scientific initiatives and external collaborations, including work related to the company's partnership with Bexorg, Inc. Dr. Car will continue to serve

Biohaven names new discovery head as CSO shifts to part-time role

Thu, 09 Jul 2026 17:01:15 -0400

Biohaven Ltd. (NYSE: BHVN) announced leadership changes in its scientific organization, effective July 13, 2026, according to a company statement.
David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, where he will lead the company's internal drug-discovery organization and oversee research programs.
Bruce Car, the company's current Chief Scientific Officer, is retiring from that role and will transition to a newly created part-time position of Chief Innovation Officer. In that capacity, Dr. Car will focus on scientific initiatives and external collaborations, including work related to the company's partnership with Bexorg, Inc. Dr. Car will continue to serve

Biohaven names new discovery head as CSO shifts to part-time role

Thu, 09 Jul 2026 17:01:15 -0400

Biohaven Ltd. (NYSE: BHVN) announced leadership changes in its scientific organization, effective July 13, 2026, according to a company statement.
David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, where he will lead the company's internal drug-discovery organization and oversee research programs.
Bruce Car, the company's current Chief Scientific Officer, is retiring from that role and will transition to a newly created part-time position of Chief Innovation Officer. In that capacity, Dr. Car will focus on scientific initiatives and external collaborations, including work related to the company's partnership with Bexorg, Inc. Dr. Car will continue to serve

Biohaven Announces Scientific Leadership Transitions

Thu, 09 Jul 2026 17:00:00 -0400

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery

Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations

Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer
NEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this

Biohaven Announces Scientific Leadership Transitions

Thu, 09 Jul 2026 17:00:00 -0400

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery

Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations

Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer
NEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this

Biohaven Announces Scientific Leadership Transitions

Thu, 09 Jul 2026 17:00:00 -0400

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery

Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations

Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer
NEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this

Biohaven Announces Scientific Leadership Transitions

Thu, 09 Jul 2026 17:00:00 -0400

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery

Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations

Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer
NEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this

Biohaven Announces Scientific Leadership Transitions

Thu, 09 Jul 2026 17:00:00 -0400

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery

Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations

Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer
NEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this

Biohaven Announces Scientific Leadership Transitions

Thu, 09 Jul 2026 17:00:00 -0400

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery

Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations

Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer
NEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this

Biohaven Announces Scientific Leadership Transitions

Thu, 09 Jul 2026 17:00:00 -0400

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery

Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations

Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer
NEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this

Biohaven Announces Scientific Leadership Transitions

Thu, 09 Jul 2026 17:00:00 -0400

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery

Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations

Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer
NEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this

Form SCHEDULE 13G/A Biohaven Ltd. Filed by: Janus Henderson Group Ltd.

Wed, 08 Jul 2026 17:44:00 -0400
si-local-file:///var/storage/secattach/20260708/26748491.html

Form SCHEDULE 13G/A Biohaven Ltd. Filed by: Janus Henderson Group Ltd.

Wed, 08 Jul 2026 17:44:00 -0400
si-local-file:///var/storage/secattach/20260708/26748491.html

Biohaven completes enrollment in focal epilepsy drug trial

Tue, 30 Jun 2026 07:31:33 -0400

Biohaven Ltd. (NYSE: BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study evaluating opakalim, a selective Kv7.2/7.3 channel activator, for the treatment of refractory focal epilepsy. Top-line results are expected in the second half of 2026.
RISE3 (NCT06309966) enrolled adult participants with refractory focal onset seizures who experienced at least four seizures per month while taking one to three concurrent antiseizure medicines (ASMs). After an eight-week observation phase, participants were randomized to opakalim 75 mg, 50 mg, or placebo once daily as adjunctive therapy for an eight-week double-blind treatment period. The primary endpoint measures

Biohaven completes enrollment in focal epilepsy drug trial

Tue, 30 Jun 2026 07:31:33 -0400

Biohaven Ltd. (NYSE: BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study evaluating opakalim, a selective Kv7.2/7.3 channel activator, for the treatment of refractory focal epilepsy. Top-line results are expected in the second half of 2026.
RISE3 (NCT06309966) enrolled adult participants with refractory focal onset seizures who experienced at least four seizures per month while taking one to three concurrent antiseizure medicines (ASMs). After an eight-week observation phase, participants were randomized to opakalim 75 mg, 50 mg, or placebo once daily as adjunctive therapy for an eight-week double-blind treatment period. The primary endpoint measures

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Tue, 30 Jun 2026 07:30:00 -0400

Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026
Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profile
In the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs
High double-blind completion rates of ~95%, and high rollover